What is it about?
During the first couple months of COVID-19 in New York City, there was limited evidence supporting use of certain medications. When patients had worsening lung function, a medication called tocilizumab was often used. We reviewed our use of tocilizumab at a dose of 400mg without concurrent steroids, and found no improvement in breathing or survival.
Featured Image
Why is it important?
Medications may work or not based on dose, timing, and if given in conjunction with other medications. Tocilizumab 400mg without steroids does not appear to be effective based on our findings.
Perspectives
In a time with a public health emergency and no data, we evaluated our own medication use to determine if interventions were effective.
Monica Mehta
NewYork-Presbyterian Hospital
Read the Original
This page is a summary of: What about tocilizumab? A retrospective study from a NYC Hospital during the COVID-19 outbreak, PLOS One, April 2021, PLOS,
DOI: 10.1371/journal.pone.0249349.
You can read the full text:
Contributors
The following have contributed to this page
